Our study deduced that dysregulation of mRNA PIK3C2A (downregulation) and TXNIP (upregulation) gene expressions among patients with CSA and those with ACS mainly STEMI patients may be helpful diagnostic biomarkers for CAD even more after the combination of these mRNAs, which could improve their diagnostic performance. This evidence concerns the gene TXNIP and coronary artery disorder.